13 Best Growth Stocks to Buy Right Now

11. ADC Therapeutics (NYSE:ADCT)

ADC Therapeutics (NYSE:ADCT) is one of the best growth stocks to buy right now. On March 10, ADC Therapeutics reported its financial and operational results for Q4 and the full-year 2025, highlighting upcoming clinical milestones for its lead product, ZYNLONTA. The company recorded Q4 net product revenue of $22.3 million and full-year revenue of $73.6 million, driven by stable demand and higher selling prices. With $261.3 million in cash and cash equivalents as of December 31, 2025, the company expects its current cash runway to extend at least into 2028.

The company is approaching several value-creating catalysts in its clinical pipeline, specifically targeting diffuse large B-cell lymphoma/DLBCL. Topline data from the LOTIS-5 Phase 3 confirmatory trial is expected in Q2 2026, with full results for both LOTIS-5 and the LOTIS-7 Phase 1b trial anticipated by year-end. If these results are positive, the company plans to pursue sBLA and potential compendia inclusions in 2027. Additionally, investigator-initiated trials are evaluating ZYNLONTA for other B-cell malignancies, including follicular lymphoma and marginal zone lymphoma, with data expected between late 2026 and mid-2027.

Financial performance for 2025 showed a significant reduction in net loss, which totaled $142.6 million for the full year compared to $157.8 million in 2024. This improvement was attributed to lower R&D expenses following the discontinuation of certain programs and a reprioritization initiated in June 2025. Total adjusted operating expenses also decreased year-over-year as ADC Therapeutics (NYSE:ADCT) optimized its organizational structure.

ADC Therapeutics (NYSE:ADCT) is a healthcare company that offers an antibody drug conjugate/ADC technology platform with flagship products that include ZYNLONTA, which is a CD19-directed ADC.